Issues
-
Cover Image
Cover Image
Immunofluorescence staining of the postpartum mouse mammary gland shows membrane-bound β-catenin (white) and nuclei (blue). YAP increases β-catenin activity to facilitate the luminal to basal transdifferentiation of mammary cells and promotes basal-like cancer formation. Targeting the YAP/TEAD4/β-catenin complex offers a potential therapeutic strategy for treating basal-like breast cancers. For details, see article by Quinn and colleagues on page 2116. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Research
Table of Contents
Breaking Insights
Review
Cancer Research Highlights
Genome and Epigenome
Loss-of-Function Variants in the Tumor-Suppressor Gene PTPN14 Confer Increased Cancer Risk
Metabolism and Chemical Biology
Fat Induces Glucose Metabolism in Nontransformed Liver Cells and Promotes Liver Tumorigenesis
Molecular Cell Biology
Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
The miR–181a–SFRP4 Axis Regulates Wnt Activation to Drive Stemness and Platinum Resistance in Ovarian Cancer
Therapeutic Targeting of DGKA-Mediated Macropinocytosis Leads to Phospholipid Reprogramming in Tuberous Sclerosis Complex
Tumor Biology and Immunology
The Irradiated Brain Microenvironment Supports Glioma Stemness and Survival via Astrocyte-Derived Transglutaminase 2
YAP and β-Catenin Cooperate to Drive Oncogenesis in Basal Breast Cancer
Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction
Tumor-Derived Pericytes Driven by EGFR Mutations Govern the Vascular and Immune Microenvironment of Gliomas
Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer
Translational Science
T Cells Expanded from PD-1+ Peripheral Blood Lymphocytes Share More Clones with Paired Tumor-Infiltrating Lymphocytes
Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer
Pronociceptive Roles of Schwann Cell–Derived Galectin-3 in Taxane-Induced Peripheral Neuropathy
Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors
Convergence and Technologies
Population and Prevention Science
Association of the Age at Menarche with Site-Specific Cancer Risks in Pooled Data from Nine Cohorts
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.